Allergies are a major cause of illness in the United States. As many as 50 million people – about one in five – have allergies. Allergies are the sixth leading cause of chronic illness among Americans and cost the U.S. economy more than $18 billion annually. What we don’t know is how many people are suffering from the side-effects of the allergy shots they take and what the economic costs are of that treatment. American College of Allergy, Asthma & Immunology. Allergy Facts.
But you may not know that most allergy shots can contain aluminum as an adjuvant, like vaccines. But expose patients to even higher levels because of the frequency that allergy shots are given. More and more research studies are linking aluminum to the ever growing rates of chronic illness, autoimmune issues and neurological disorders now prevalent in developed countries, particularly the United States. Aluminum has no reason to be inside the body and is well known to be toxic.
And when injected, our bodies cannot filter the out the known toxin. As the study below explains, injection absorption rates are near 100% versus .1-.3% for aluminum taken in through ingestion (in food or drinks). The study states: “This includes a difference in absorption (100% of aluminium absorbed via the parenteral route  versus 0.1–3% via the gastrointestinal route.”
Aluminium in allergen-specific subcutaneous immunotherapy – A German perspective. Vaccine, 2014
“Aluminium will accumulate in the human body over the life-time of an individual and undoubtedly has the potential to exert chronic toxic effects, such as neurotoxicity. Predisposing an individual to an unnecessary high body burden of aluminium should be avoided and could reasonably be considered a cause for triggering the onset or progression of a number of conditions and disease states mentioned in this paper [autoimmune disease, neurological disorders such as dementia and Alzheimer’s].”
“Numerous injections with higher proportions of aluminium-adjuvant per injection (in comparison to vaccines) are applied in subcutaneous immunotherapy (SCIT) and will significantly contribute to a higher cumulative life dose of aluminium. While the human body may cope robustly with a daily aluminium overload from the environment, regulatory cumulative threshold values in immunotherapy need further addressing. Based on the current literature, predisposing an individual to an unusually high level of aluminium, such as through subcutaneous immunotherapy, has the potential to form focal accumulations in the body with the propensity to exert forms of toxicity.”
Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy. Allergy, Asthma & Clinical Immunology, 2014.
According to Christopher Exley, PhD, professor of bioinorganic chemistry at Keele University in the United Kingdom in this 2014 study:
“Aluminium-based adjuvants are the most commonly used adjuvant in sub-cutaneous allergy immunotherapy (SCIT). Approximately 75% of all such adjuvant-based therapies include an aluminium salt. In parallel with the use of aluminium-based adjuvants in vaccinations these adjuvants have been in use in allergy immunotherapies for over 80 years.
There are very few data purporting to the safety of aluminium adjuvants in allergy immunotherapy and particularly so in relation to longer term health effects.” adds Dr. Exley, one of the leading world experts on aluminum.
Our health is the most important thing we have. We need to be cautious when considering any and all medical treatments, including allergy shots.